No summary has been written for this.
Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies designed to harness the immune system and target specific molecular pathways to inhibit cancer. The company's product pipeline includes Vebreltinib (APL-101), an oral selective c-Met inhibitor in Phase 2 trials for non-small cell lung cancer and solid tumors with MET dysregulation; APL-102, a multi-tyrosine kinase inhibitor in Phase 1 development; and APL-122, targeting ErbB signaling pathways for brain cancers in Phase 1 dose escalation trials. Additionally, Apollomics develops immuno-oncology candidates including APL-501, APL-502, and APL-801, as well as uproleselan (APL-106), an E-Selectin antagonist with potential applications in acute myeloid leukemia when used alongside standard chemotherapy. Founded in 2015 and headquartered in Foster City, California, the company addresses unmet medical needs in oncology through its combination approach to cancer treatment.
United States
The latest articles about APLMW.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about APLMW also mention these. Each card shows that asset’s own numbers for the past 24 hours.